In addition to prevailing alterations in AR expression and function, approximately half of prostate cancer samples harbor an oncogenic gene fusion combining androgen-regulated transmembrane protease serine 2 (TMPRSS2) with oncogenic ETS transcription factors [10]. The gene discussed is TMPRSS2; the disease is prostate carcinoma.